PURPOSE:

This workshop will have an overview of the development and implementation of risk sharing arrangement (RSA) and provide in-depth presentation and discussion on the role of real-world evidence (RWE) and budget impact analysis (BIA) in supporting the development and execution of RSA. The participants will gain a comprehensive understanding of the RSA practice and unique perspectives of the application of RWE and BIA in supporting RSA.

DESCRIPTION:

RSA between pharmaceutical companies and payers are increasingly practiced as an additional approach to address the value and sustainability of healthcare funding. It allows the patients to have earlier access to the medicines, particularly innovative medicines, by speeding up the reimbursement process in the context of uncertainty about the clinical and economics evidence. Broadly speaking, RSA can be subdivided into either financial-based models or outcome/performance-based models. Both RWE and BIA become critical components to support the design and execution of the RSA. With Prof Jiu-Hong Wu chairing and moderating, Prof Shanlian Hu will first present an overview of the international efforts and recent development of RSA. Prof Shu Chuen Li and Dr Fei-Li Zhao will focus on discussing how to use the RWE and BIA to support the RSA from different perspectives with presenting case studies. The panel will highlight the challenges and discuss the possible solutions, particularly in the context of Asian countries. We will engage all participants, especially those from Asian countries, to share their own country’s experiences and challenges through a round-table discussion, and to leverage the results from discussion to contribution to the improvement of efficiency of RSA practice in Asia.